Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin-releasing hormone agonist short regimen on alternate days and an antagonist protocol for assisted fertilization treatments

Fertility and Sterility

Volumn 99, Issue 6, 2013, Pages 1615-1622

  Maldonado, Luiz Guilherme Louzada ^a   Franco Jr , José Gonçalves ^a,b   Setti, Amanda Souza ^c,d   Iaconelli Jr , Assumpto ^c,d   Borges Jr , Edson ^c,d  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b Center for Human Reproduction Prof Franco Jr   (Brazil)

^c Sapientiae Institute Educational and Research Center in Assisted Reproduction   (Brazil)

^d Fertility Assisted Fertilization Center   (Brazil)

Author keywords

Controlled ovarian stimulation; GnRHa; GnRHant ICSI; pituitary down regulation

Indexed keywords

CETRORELIX; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOWN REGULATION; DRUG DOSE REDUCTION; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; HUMAN; HUMAN CELL; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; MALE; OOCYTE; OUTCOME ASSESSMENT; PREGNANCY RATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION;

ADULT; COST-BENEFIT ANALYSIS; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; PITUITARY GLAND; PREGNANCY; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TREATMENT OUTCOME; TRIPTORELIN PAMOATE;

EID: 84876970476     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2013.01.095     Document Type: Article

References (35)

1. M. Cavagna, L.G. Maldonado, T.C. de Souza Bonetti, D.P. de Almeida Ferreira Braga, A. Iaconelli Jr., and E. Borges Jr. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression Fertil Steril 94 2010 167 172
2. E. Karatekeli, H. Ozornek, H. Jamal, E. Ergin, and B. Ongun Administration of alternate day triptorelin for controlled ovarian hyperstimulation is cost effective Fertil Steril 85 2006 518 519
3. L.P. Cheung, P.M. Lam, I.H. Lok, T.T. Chiu, S.Y. Yeung, and C.C. Tjer GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial Hum Reprod 20 2005 616 621
4. K. Diedrich, C. Diedrich, E. Santos, C. Zoll, S. Al-Hasani, and T. Reissmann Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation Hum Reprod 9 1994 788 791
5. D. Bodri, S.K. Sunkara, and A. Coomarasamy Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-Analysis Fertil Steril 95 2011 164 169
6. E.R. Hernandez Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists Hum Reprod 15 2000 1211 1216
7. H. Al-Inany, and M. Aboulghar GnRH antagonist in assisted reproduction: a Cochrane review Hum Reprod 17 2002 874 885
8. M.A. Akman, H.F. Erden, S.B. Tosun, N. Bayazit, E. Aksoy, and M. Bahceci Addition of GnRH antagonist in cycles of poor responders undergoing IVF Hum Reprod 15 2000 2145 2147
9. E.M. Kolibianakis, J. Collins, B.C. Tarlatzis, P. Devroey, K. Diedrich, and G. Griesinger Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-Analysis Hum Reprod Update 12 2006 651 671
10. R. Orvieto, R. Nahum, J. Rabinson, O. Gemer, E.Y. Anteby, and S. Meltcer Ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist for patients with repeated IVF failures and poor embryo quality Fertil Steril 91 2009 1398 1400
11. H.J. Out, D.D. Braat, B.M. Lintsen, T. Gurgan, O. Bukulmez, and O. Gokmen Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation Hum Reprod 15 2000 29 35
12. E. Escudero, E. Bosch, J. Crespo, C. Simon, J. Remohi, and A. Pellicer Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients Fertil Steril 81 2004 562 566
13. E.M. Kolibianakis, B. Tarlatzis, and P. Devroey GnRH antagonists in IVF Reprod Biomed Online 10 2005 705 712
14. K. Koichi, N. Yukiko, K. Shima, and S. Sachiko Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol J Assist Reprod Genet 23 2006 223 228
15. P. Serafini, I. Yadid, E.L. Motta, J.R. Alegretti, J. Fioravanti, and M. Coslovsky Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial Fertil Steril 86 2006 830 838
16. M. Filicori, G.E. Cognigni, A. Samara, S. Melappioni, T. Perri, and B. Cantelli The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction Hum Reprod Update 8 2002 543 557
17. L. Dal Prato, A. Borini, G. Coticchio, M. Cattoli, and C. Flamigni Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study Hum Reprod 19 2004 2200 2205
18. M. Sbracia, J. Colabianchi, A. Giallonardo, P. Giannini, C. Piscitelli, and F. Morgia Cetrorelix protocol versus gonadotropin-releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40 Fertil Steril 91 2009 1842 1847
19. P. Devroey, M. Aboulghar, J. Garcia-Velasco, G. Griesinger, P. Humaidan, and E. Kolibianakis Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment Hum Reprod 24 2009 764 774
20. J.S. Younis, S. Soltsman, I. Izhaki, O. Radin, S. Bar-Ami, and M. Ben-Ami Early and short follicular gonadotropin-releasing hormone antagonist supplementation improves the meiotic status and competence of retrieved oocytes in in vitro fertilization-embryo transfer cycles Fertil Steril 94 2010 1350 1355
21. M. Bloch, F. Azem, I. Aharonov, I. Ben Avi, Y. Yagil, and S. Schreiber GnRH-Agonist induced depressive and anxiety symptoms during in vitro fertilization-embryo transfer cycles Fertil Steril 95 2011 307 309
22. C. Hayden GnRH analogues: applications in assisted reproductive techniques Eur J Endocrinol 159 Suppl 1 2008 S17 S25
23. A.C. van Loenen, J.A. Huirne, R. Schats, P.G. Hompes, and C.B. Lambalk GnRH agonists, antagonists, and assisted conception Semin Reprod Med 20 2002 349 364
24. H.G. Al-Inany, A.M. Abou-Setta, and M. Aboulghar Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review Reprod Biomed Online 14 2007 640 649
25. A.J. van Dongen, T.E. Verhagen, J.C. Dumoulin, J.A. Land, and J.L. Evers Reasons for dropping out from a waiting list for in vitro fertilization Fertil Steril 94 2010 1713 1716
26. S.M. Mourad, W.L. Nelen, R.P. Akkermans, J.H. Vollebergh, R.P. Grol, and R.P. Hermens Determinants of patients' experiences and satisfaction with fertility care Fertil Steril 94 2010 1254 1260
27. A.D. Domar, K. Smith, L. Conboy, M. Iannone, and M. Alper A prospective investigation into the reasons why insured United States patients drop out of in vitro fertilization treatment Fertil Steril 94 2010 1457 1459
28. W. Ombelet, and R. Campo Affordable IVF for developing countries Reprod Biomed Online 15 2007 257 265
29. R.M. Janssens, C.B. Lambalk, J.P. Vermeiden, R. Schats, and J. Schoemaker In-vitro fertilization in a spontaneous cycle: easy, cheap and realistic Hum Reprod 15 2000 314 318
30. C. Blockeel, M. De Vos, W. Verpoest, D. Stoop, P. Haentjens, and P. Devroey Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-Antagonist cycle? A pilot study Hum Reprod 24 2009 2910 2916
31. M. Filicori, G.E. Cognigni, E. Gamberini, L. Parmegiani, E. Troilo, and B. Roset Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation Fertil Steril 84 2005 394 401
32. F. Fabregues, J. Penarrubia, M. Creus, R. Casamitjana, J.A. Vanrell, and J. Balasch Effect of halving the daily dose of triptorelin at the start of ovarian stimulation on hormone serum levels and the outcome of in vitro fertilization Fertil Steril 83 2005 785 788
33. E. Loumaye, L. Vankrieken, S. Depreester, I. Psalti, S. de Cooman, and K. Thomas Hormonal changes induced by short-term administration of gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in vitro fertilization and their consequences for embryo development Fertil Steril 51 1989 105 111
34. R. Homburg, N.A. Armar, A. Eshel, J. Adams, and H.S. Jacobs Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome BMJ 297 1988 1024 1026
35. B.C. Tarlatzis, G. Grimbizis, F. Pournaropoulos, J. Bontis, S. Lagos, and E. Spanos The prognostic value of basal luteinizing hormone:follicle- stimulating hormone ratio in the treatment of patients with polycystic ovarian syndrome by assisted reproduction techniques Hum Reprod 10 1995 2545 2549